ВИЧ-ИНФЕКЦИЯ И СЕРДЕЧНО-СОСУДИСТЫЕ ОСЛОЖНЕНИЯ
Аннотация
В связи с увеличением числа ВИЧ-инфицированных пациентов и сроков их дожития значимость сердечно-сосудистой патологии в структуре осложнений ВИЧ возрастает. В статье рассмотрены наиболее типичные осложнения, развивающиеся у этой группы пациентов. Основное внимание уделено тактике ведения дилатационной кардиомиопатии и перикардиальных выпотов у ВИЧ-инфицированных. Также описаны коронарная болезнь сердца и ее связь с приемом антиретровирусных препаратов и наличием ВИЧ-инфекции.
Об авторах
C. C. Якушин
ГОУ ВПО Рязанский государственный медицинский университет Минздравсоцразвития России
Россия
Россия
Е. В. Филиппов
ГОУ ВПО Рязанский государственный медицинский университет Минздравсоцразвития России
Россия
Россия
Список литературы
1. Global report: UNAIDS report on the global AIDS epidemic 2010. Available from: www.unaids.org/en/
2. media/unaids/contentassets/documents/unaidspublication/2010/20101123_globalreport_en.pdf
3. Bozzette S., Ake C.F., Tam H.K., et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702–10.
4. Global HIV/AIDS Medicine. Volberding P.A., Sande M.A., Lange J., et al. eds. Philadelphia, PA: WB Saunders, 2008.
5. Barbaro G. Cardiovascular manifestations of HIV infection. Circulation 2002;106:1420–5.
6. Currie P.F., Jacob A.J., Foreman A.R., et al. Heart muscle disease related to HIV infection: prognostic implications. BMJ 1994;309:1605–7.
7. Barbaro G., Di Lorenzo G., Soldini M., et al. Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS (GISCA).
8. Circulation 1999;100:933–9.
9. Lipshultz S.E., Easley K.A., Orav E.J., et al. Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric
10. Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 1998;97:1246–56.
11. Currie P.F., Boon N.A. Immunopathogenesis of HIV-related heart muscle disease: current perspectives. AIDS 2003;17(Suppl 1):21–8.
12. Barbaro G. Heart and HAART: Two sides of the coin for HIV-associated cardiology issues. World J Cardiol 2010;2(3):53–7.
13. Lipshultz S.E., Fisher S.D., Lai W.W., Miller T.L. Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS 2003;17(Suppl 1):96–122.
14. Lipshultz S.E., Orav E.J., Sanders S.P., Colan S.D. Immunoglobulins and left ventricular structure and function in pediatric HIV infection. Circulation 1995;92:2220–5.
15. Barbaro G. Reversible right ventricular dysfunction in HIV-infected patients. South Med J 2006;99:197.
16. Estok L., Wallach F. Cardiac tamponade in a patient with AIDS: a review of pericardial disease in patients with HIV infection. Mt Sinai J Med 1998;65:33–9.
17. Heidenreich P.A., Eisenberg M.J., Kee L.L., et al. Pericardial effusion in AIDS. Incidence and survival. Circulation 1995;92:3229–34.
18. Mesa R.A., Edell E.S., Dunn W.F., Edwards W.D. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc 1998;73:37–45.
19. Saidi A., Bricker J.T. Pulmonary hypertension in patients infected with HIV. In: Cardiology in AIDS. Lipshultz S.E. ed. NY: Chapman & Hall, 1998; p. 255–63.
20. Sitbon O., Gressin V., Speich R., et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;170:1212–7.
21. Cea-Calvo L., Escribano Subias P., Tello de Menesses R., et al. Treatment of HIV-associated pulmonary hypertension with treprostinil. Rev Esp Cardiol 2003;56:421–5.
22. Nunes H., Humbert M., Sitbon O., et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167:1433–9.
23. Rerkpattanapipat P., Wongpraparut N., Jacobs L.E., Kotler M.N. Cardiac manifestations of acquired
24. immunodeficiency syndrome. Arch Intern Med 2000;160:602–8.
25. Kaul S., Fishbein M.C., Siegel R.J. Cardiac manifestations of acquired immune deficiency syndrome: a 1991 update. Am Heart J 1991;122:535–44.
26. Nahass R.G., Weinstein M.P., Bartels J., Gocke D.J. Infective endocarditis in intravenous drug users: a comparison of human immunodeficiency virus type 1-negative and-positive patients. J Infect Dis 1990;162:967–70.
27. Jenson H.B., Pollock B.H. Cardiac cancers in HIV-infected patients. In: Cardiology in AIDS. Lipshultz S.E. ed. NY: Chapman & Hall, 1998; p. 255–63.
28. Bruno R., Sacchi P., Filice G. Overview on the incidence and the characteristics of HIV-related opportunistic infections and neoplasms of the heart: Impact of highly active antiretroviral therapy. AIDS 2003;17(Suppl 1):83–7.
29. Aboulafia D.M., Bush R., Picozzi V.J. Cardiac tamponade due to primary pericardial lymphoma in a patient with AIDS. Chest 1994;106:1295–9.
30. Rangasetty U.C., Rahman A.M., Hussain N. Reversible right ventricular dysfunction in patients with HIV infection. South Med J 2006;99(3):274–8.
31. Stein J.H. Managing cardiovascular risk in patients with HIV infection. J Acquir Immun Defic Syndr 2005;38:115–23.
32. Tabib A., Greenland T., Mercier I., et al. Coronary lesions in young HIV-positive subjects at necropsy. Lancet 1992;340:730.
33. Constans J., Marchand J.M., Conri C., et al. Asymptomatic atherosclerosis in HIVpositive patients: A case-control ultrasound study. Ann Med 1995;27:683–5.
34. Aoun S., Ramos E. Hypertension in the HIV-infected patient. Curr Hypertens Rep 2000;2:478–81.
35. Sattler F.R., Qian D., Louie S., et al. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001;15:2001–10.
36. Grunfeld C., Pang M., Doerrler W., et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045–52.
37. Tsiodras S., Mantzoros C., Hammer S., Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000;160:2050–6.
38. Dube M.P., Stein J.H., Aberg J.A., et al.; Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected
39. adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;37:613–27.
40. Correia D., Rodrigues De Resende L.A., Molina R.J., et al. Power spectral analysis of heart rate variability in HIV-infected and AIDS patients. Pacing Clin Electrophysiol 2006;29:53–8.
41. Sani M.U., Okeahialam B.N. QT interval prolongation in patients with HIV and AIDS. J Natl Med Assoc
42. ;97:1657–61.
43. Nordin C., Kohli A., Beca S., et al. Importance of hepatitis C coinfection in the development of QT prolongation in HIV-infected patients. J Electrocardiol 2006;39:199–205.
44. Oxford handbook of cardiology. P. Ramrakha, J. Hill, eds. NY: Oxford University Press, 2006.
Для цитирования:
Якушин C.C., Филиппов Е.В. ВИЧ-ИНФЕКЦИЯ И СЕРДЕЧНО-СОСУДИСТЫЕ ОСЛОЖНЕНИЯ. Клиницист. 2011;5(2):6-12. https://doi.org/10.17650/1818-8338-2011-2-6-12
For citation:
Yakushin S.S., Filippov E.V. HIV INFECTION AND CARDIOVASCULAR COMPLICATIONS. The Clinician. 2011;5(2):6-12. (In Russ.) https://doi.org/10.17650/1818-8338-2011-2-6-12
Просмотров: 482
Послать статью по эл. почте 